Published in Arch Intern Med on June 27, 2005
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | NCT00000542
Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation (2008) 2.06
2009 Canadian Hypertension Education Program recommendations: an annual update. Can Fam Physician (2009) 2.03
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol (2006) 1.67
2010 Canadian Hypertension Education Program recommendations: An annual update. Can Fam Physician (2010) 1.45
Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Med (2016) 1.40
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) (2008) 1.21
Hypertension in people with type 2 diabetes: Update on pharmacologic management. Can Fam Physician (2011) 1.17
Understanding the quality chasm for hypertension control in diabetes: a structured review of "co-maneuvers" used in clinical trials. J Am Board Fam Med (2007) 1.13
Hypertension in diabetes: a call to action. Can J Cardiol (2009) 1.10
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med (2008) 1.09
Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes (2015) 1.06
Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. CMAJ (2008) 1.04
Diabetes & coronary heart disease: current perspectives. Indian J Med Res (2010) 1.03
Antihypertensive medications and blood sugar: theories and implications. Can J Cardiol (2006) 1.02
Update on the Canadian Diabetes Association 2008 clinical practice guidelines. Can Fam Physician (2009) 0.99
Achieved blood pressures in the secondary prevention of small subcortical strokes (SPS3) study: challenges and lessons learned. Am J Hypertens (2014) 0.97
Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. J Neurol (2009) 0.91
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag (2009) 0.90
Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex. Hypertension (2013) 0.90
Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial. J Clin Hypertens (Greenwich) (2009) 0.89
Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.87
Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study. Cardiovasc Diabetol (2012) 0.85
Highlights and summary of the 2006 Canadian Hypertension Education Program recommendations. Can J Cardiol (2006) 0.83
Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus. Kidney Int Suppl (2011) (2012) 0.79
RAS blockade for every diabetic patient: pro and con. Diabetes Care (2011) 0.79
Does renin angiotensin system blockade deserve preferred status over other anti-hypertensive medications for the treatment of people with diabetes? Ann Transl Med (2016) 0.79
First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation. Cardiovasc Diabetol (2008) 0.78
Impact of chronic diuretic treatment on glucose homeostasis. Diabetol Metab Syndr (2013) 0.77
Uncontrolled home blood pressure in the morning is associated with nephropathy in Japanese type 2 diabetes. Heart Vessels (2011) 0.76
Emerging drug combinations to optimize renovascular protection and blood pressure goals. Int J Nephrol Renovasc Dis (2012) 0.76
Rebuttal: Do beta-blockers have a role in treating hypertension? No. Can Fam Physician (2007) 0.75
Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]). Am J Cardiol (2015) 0.75
Substudies of ALLHAT and Heart Protection Study. Prev Cardiol (2005) 0.75
Blood pressure control in type 2 diabetic patients. Cardiovasc Diabetol (2017) 0.75
[ESC/EASD joint guidelines on diabetes and cardiovascular diseases]. Herz (2009) 0.75
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension (2008) 6.96
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation (2008) 5.26
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care (2010) 4.10
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA (2005) 3.89
Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA (2004) 3.85
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol (2007) 3.39
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control (2002) 3.27
Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol (2011) 3.25
Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation (2012) 2.99
Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 2.98
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med (2006) 2.81
Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study. BMJ (2011) 2.80
Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care (2008) 2.76
Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med (2013) 2.74
Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care (2002) 2.72
Comparison between an automated and manual sphygmomanometer in a population survey. Am J Hypertens (2008) 2.70
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich) (2013) 2.64
Meta-analysis of statin effects in women versus men. J Am Coll Cardiol (2012) 2.56
Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol (2005) 2.52
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation (2008) 2.51
The Women's Health Initiative: The food environment, neighborhood socioeconomic status, BMI, and blood pressure. Obesity (Silver Spring) (2011) 2.50
Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation (2007) 2.50
Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med (2015) 2.42
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Abdominal aortic aneurysm events in the women's health initiative: cohort study. BMJ (2008) 2.41
Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) (2005) 2.35
Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ (2011) 2.34
Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab (2006) 2.34
Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. J Am Coll Cardiol (2010) 2.34
J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J (2010) 2.32
Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med (2014) 2.31
Calcium and vitamin D supplementation and cognitive impairment in the women's health initiative. J Am Geriatr Soc (2012) 2.30
The Society for Clinical Trials supports United States legislation mandating trials registration. Position paper. Clin Trials (2004) 2.21
Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA (2011) 2.21
Sleep disturbance and incidence of thyroid cancer in postmenopausal women the Women's Health Initiative. Am J Epidemiol (2012) 2.20
Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial. J Gen Intern Med (2014) 2.20
Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women. Diabetes (2007) 2.19
ALLHAT: setting the record straight. Ann Intern Med (2004) 2.19
Diabetes and lung cancer among postmenopausal women. Diabetes Care (2012) 2.17
Diabetes and hypertension: the bad companions. Lancet (2012) 2.10
Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation (2008) 2.06
The Cardiovascular Research Network: a new paradigm for cardiovascular quality and outcomes research. Circ Cardiovasc Qual Outcomes (2008) 2.03